title: Statin intolerance: why and what to do - with a focus on diabetic people.
abstract: The standards of medical care in diabetes recommend that statin therapy is added to lifestyle therapy for diabetic patients with overt cardiovascular disease (LDL cholesterol goal <70 mg/dl), or without cardiovascular disease who are over the age of 40 years and who have one or more other cardiovascular disease risk factors (LDL cholesterol goal <100 mg/dl). In order to reach strict LDL targets, high doses of statins may be required. However, the frequency of statin associated adverse effects and statin intolerance in clinical practice is high (up to 10-15% of statin users) especially at muscle level. The review overviews: 1) the known or hypothesised mechanisms through which causal and contributing factors are associated with adverse effects in diabetic people, and 2) the rationale of strategies for managing statin intolerant patients.
authors: Department of Clinical and Experimental Medicine, University of Pisa, Italy. elena.matteucci@med.uipi.it
authors: E
authors: E
authors: Matteucci
authors: O
authors: O
authors: Giampietro
mesh_terms: D000214:Acyl Coenzyme A / Q000378:metabolism; D000818:Animals; D002318:Cardiovascular Diseases / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D048909:Diabetes Complications / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use*; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000214:Acyl Coenzyme A; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C008047:3-hydroxy-3-methylglutaryl-coenzyme A